ATE441706T1 - Konjugate mit biologisch abbaubarem polymer und verwendung dafür - Google Patents
Konjugate mit biologisch abbaubarem polymer und verwendung dafürInfo
- Publication number
- ATE441706T1 ATE441706T1 AT03716070T AT03716070T ATE441706T1 AT E441706 T1 ATE441706 T1 AT E441706T1 AT 03716070 T AT03716070 T AT 03716070T AT 03716070 T AT03716070 T AT 03716070T AT E441706 T1 ATE441706 T1 AT E441706T1
- Authority
- AT
- Austria
- Prior art keywords
- biodegradable polymer
- polymer
- apyrase
- polymer conjugates
- biologically active
- Prior art date
Links
- 229920002988 biodegradable polymer Polymers 0.000 title abstract 2
- 239000004621 biodegradable polymer Substances 0.000 title abstract 2
- 102000007347 Apyrase Human genes 0.000 abstract 2
- 108010007730 Apyrase Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L59/00—Compositions of polyacetals; Compositions of derivatives of polyacetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biological Depolymerization Polymers (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35830302P | 2002-02-20 | 2002-02-20 | |
| PCT/US2003/004845 WO2003070823A2 (en) | 2002-02-20 | 2003-02-19 | Conjugates comprising a biodegradable polymer and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE441706T1 true ATE441706T1 (de) | 2009-09-15 |
Family
ID=27757725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03716070T ATE441706T1 (de) | 2002-02-20 | 2003-02-19 | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7785618B2 (de) |
| EP (2) | EP1585817B1 (de) |
| AT (1) | ATE441706T1 (de) |
| AU (1) | AU2003219796A1 (de) |
| DE (1) | DE60329126D1 (de) |
| WO (1) | WO2003070823A2 (de) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US20060177416A1 (en) | 2003-10-14 | 2006-08-10 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
| ATE441706T1 (de) * | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| EP1534269B1 (de) | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxim-konjugate und verfahren zu ihrer bildung und verwendung |
| US7790150B2 (en) | 2003-09-05 | 2010-09-07 | The General Hospital Corporation | Dual phase drug release system |
| WO2006108052A2 (en) | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| JP5192384B2 (ja) | 2005-09-22 | 2013-05-08 | メディバス エルエルシー | ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法 |
| JP5178520B2 (ja) | 2005-09-22 | 2013-04-10 | メディバス エルエルシー | 固体ポリマー送達組成物およびその使用法 |
| DE102006046411A1 (de) * | 2006-09-20 | 2008-03-27 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von akutem Lungenversagen (ALI) |
| US7713235B2 (en) * | 2006-10-04 | 2010-05-11 | Pathway Medical Technologies, Inc. | Interventional catheters incorporating an active aspiration system |
| JP5541594B2 (ja) * | 2006-11-07 | 2014-07-09 | ディーエスエム アイピー アセッツ ビー．ブイ． | 生体分子部分を含むカルバメート、チオカルバメートまたはカルバミド |
| CN102978185B (zh) | 2007-01-18 | 2015-02-11 | 建新公司 | 包含氨基氧基基团的寡糖及其轭合物 |
| WO2008104200A1 (en) * | 2007-03-01 | 2008-09-04 | Gelato Corporation N.V. | Use of apyrase for the treatment of a pathology resulting from endotoxin activity |
| US8202528B2 (en) * | 2007-06-05 | 2012-06-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices with elastomeric block copolymer coatings |
| CA2700441A1 (en) | 2007-09-24 | 2009-04-02 | Noxxon Pharma Ag | C5a binding nucleic acids |
| CN101990441A (zh) * | 2007-11-28 | 2011-03-23 | 默萨那治疗学股份有限公司 | 生物相容的生物可降解的烟曲霉素类似物轭合物 |
| US8289514B2 (en) * | 2008-03-05 | 2012-10-16 | Aggredyne, Inc. | Systems for measuring properties of a physiological fluid suspension |
| US20090292042A1 (en) * | 2008-05-21 | 2009-11-26 | Patterson Greg S | Biodegradable material and plant container |
| WO2010033995A1 (en) | 2008-09-22 | 2010-03-25 | Tyrx Pharma, Inc. | Linear polyesteramides from aminophenolic esters |
| CN102307473A (zh) * | 2008-12-10 | 2012-01-04 | 摩萨纳医疗有限公司 | 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂 |
| PL2889043T3 (pl) | 2008-12-16 | 2019-09-30 | Genzyme Corporation | Syntetyczne związki pośrednie do wytwarzania koniugatów oligosacharyd-białko |
| WO2010108657A2 (en) | 2009-03-23 | 2010-09-30 | Noxxon Pharma Ag | C5a binding nucleic acids and the use thereof |
| US9839628B2 (en) | 2009-06-01 | 2017-12-12 | Tyrx, Inc. | Compositions and methods for preventing sternal wound infections |
| ITAN20100002A1 (it) * | 2010-01-25 | 2011-07-26 | Biolog S R L | Materiale polimerico sintentico biodegradabile |
| EP2553019A1 (de) | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modifizierte polymere zur freisetzung von polynukleotiden, verfahren zu ihrer herstellung und verfahren zu ihrer verwendung |
| EP2561079A1 (de) | 2010-04-21 | 2013-02-27 | Noxxon Pharma AG | Lipidbindende nukleinsäuren |
| KR101210713B1 (ko) * | 2010-06-29 | 2012-12-10 | 가톨릭대학교 산학협력단 | 온도 민감성 생리활성 물질 전달체 및 이의 제조방법 |
| JP2013537552A (ja) | 2010-08-18 | 2013-10-03 | デル マー ファーマスーティカルズ | ジアンヒドロガラクチトール及びジアセチルジアンヒドロガラクチトール等の置換ヘキシトールを含む準最適に投与された化合物の治療的有効性を改良するための組成物及び方法 |
| WO2012025251A1 (en) | 2010-08-27 | 2012-03-01 | Noxxon Pharma Ag | Nucleic acids for treatment of chronic complications of diabetes |
| CN103108641B (zh) | 2010-09-09 | 2016-01-13 | 诺松制药股份公司 | Sdf-1结合性核酸及其在癌症治疗中的用途 |
| JP2014503187A (ja) | 2010-10-29 | 2014-02-13 | ノクソン ファーマ エージー | 身体からヘプシジンを除去するためのヘプシジン結合核酸の使用 |
| EP2663640B1 (de) | 2011-01-10 | 2020-11-04 | APTARION biotech AG | Nukleinsäuremolekül mit bindungsaffinität für ein zielmolekül und verfahren zu seiner erzeugung |
| CA2837840C (en) * | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
| EP2723801B1 (de) | 2011-06-23 | 2017-01-18 | DSM IP Assets B.V. | Neue biologisch abbaubare polyesteramid-copolymere zur arzneimittelabgabe |
| EP2758043A4 (de) | 2011-08-17 | 2016-02-24 | Dennis M Brown | Zusammensetzungen und verfahren zur erhöhung des therapeutischen nutzens von suboptimal verabreichten chemischen verbindungen einschliesslich substituierter hexitole wie dibromodulcitol |
| KR20140083039A (ko) | 2011-10-21 | 2014-07-03 | 녹손 파르마 아게 | 글루카곤 결합형 핵산 |
| BR112014016939A2 (pt) | 2012-01-10 | 2019-09-24 | Noxxon Pharma Ag | ácidos nucleicos que se ligam especificamente a cgrp |
| US9518265B2 (en) | 2012-01-10 | 2016-12-13 | Noxxon Pharma Ag | C5a binding nucleic acids |
| MX385227B (es) | 2012-01-20 | 2025-03-14 | Del Mar Pharmaceuticals | Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y análogos para tratar enfermedad neoplásica y células madre de cáncer que incluyen glioblastoma multiforme y meduloblastoma. |
| AU2013234955A1 (en) | 2012-03-23 | 2014-11-13 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| WO2013169600A1 (en) | 2012-05-09 | 2013-11-14 | Delmar Pharmaceuticals | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
| SG10201610869TA (en) | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
| US9987336B2 (en) | 2012-08-10 | 2018-06-05 | Rutgers, The State University Of New Jersey | Attenuating or treating sepsis or septic shock |
| EP2983674A4 (de) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutischer nutzen suboptimal verabreichter chemischer verbindungen |
| WO2014169256A2 (en) * | 2013-04-11 | 2014-10-16 | Vanderbilt University | Polyplexes |
| CA2928568A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| WO2015062743A1 (en) | 2013-11-04 | 2015-05-07 | Noxxon Pharma Ag | Means and methods for the treatment of nephropathy |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| US10293044B2 (en) | 2014-04-18 | 2019-05-21 | Auburn University | Particulate formulations for improving feed conversion rate in a subject |
| EP3134118B1 (de) | 2014-04-18 | 2020-01-22 | Auburn University | Partikelförmige impfstoffformulierungen zur induzierung von angeborener und adaptiver immunität |
| CN107106509B (zh) | 2014-12-18 | 2021-11-30 | 帝斯曼知识产权资产管理有限公司 | 用于递送酸敏感药物的药物递送系统 |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| TWI852735B (zh) | 2015-12-04 | 2024-08-11 | 美商思進公司 | 四級胺化妥布賴森(tubulysin)化合物之結合物 |
| GB201522541D0 (en) * | 2015-12-21 | 2016-02-03 | Inst Research In Biomedicine | Compositions |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| EP3443095A1 (de) | 2016-04-15 | 2019-02-20 | Noxxon Pharma AG | Verfahren zur modulation der anzahl und der verteilung von tumorinfiltrierenden leukozyten bei tumoren |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12599579B2 (en) | 2016-04-19 | 2026-04-14 | Axcess Global Sciences, Llc | Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US12622889B2 (en) | 2016-04-19 | 2026-05-12 | Axcess Global Sciences, Llc | S-β-hydroxybutyrate esters for improving metabolic function |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US10583199B2 (en) | 2016-04-26 | 2020-03-10 | Northwestern University | Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| CN109303923B (zh) * | 2018-11-09 | 2021-05-11 | 东南大学 | 一种制备类羟基磷灰石成分的纳米簇凝胶的方法 |
| JP2022520560A (ja) * | 2019-02-11 | 2022-03-31 | アクセス・グローバル・サイエンシーズ・エルエルシー | ベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法 |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| CA3160955A1 (en) | 2019-11-12 | 2021-05-20 | Dsm Ip Assets B.V. | Polyesteramide copolymers possessing high glass transition temperatures |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| EP4306640A1 (de) | 2022-06-21 | 2024-01-17 | TME Pharma AG | Verfahren zur behandlung eines tumors in einem patienten |
| WO2023247651A1 (en) | 2022-06-21 | 2023-12-28 | TME Pharma AG | Methods for treating a tumor in a subject |
| TW202602466A (zh) | 2024-03-20 | 2026-01-16 | 德商艾普塔里昂生技公司 | 以Ｃ５ａ抑制劑治療疾病之方法 |
| EP4620474A1 (de) | 2024-03-20 | 2025-09-24 | APTARION biotech AG | Verfahren zur behandlung einer erkrankung mit einem c5a-hemmer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES437153A1 (es) * | 1974-05-06 | 1977-04-16 | Marburgnlahn | Procedimiento para la preparacion de un compuesto biologica-mente activo a base de poli(hidroximetileno) o poli(carbona-to de vinileno). |
| SU761477A1 (ru) * | 1978-07-10 | 1980-09-07 | Datse Yu Baltsere | Способ получения водорастворимого препарата целлюлазы . . 1 |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4766072A (en) | 1985-07-17 | 1988-08-23 | Promega Corporation | Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence |
| US4729956A (en) * | 1986-05-01 | 1988-03-08 | Phillips Petroleum Company | Stabilized alcohol oxidase compositions and method for producing same |
| US4843147A (en) * | 1986-11-06 | 1989-06-27 | University Of British Columbia | Anhydrous enhanced coupling of proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8826429D0 (en) * | 1988-11-11 | 1988-12-14 | Univ Leeds Ind Service Ltd | Enzyme stabilisation systems |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| JPH03158758A (ja) * | 1989-11-17 | 1991-07-08 | Tosoh Corp | デキストランを介して結合した二以上の物質の複合体及び該複合体の製造方法 |
| US5221495A (en) * | 1990-04-13 | 1993-06-22 | Colgate-Palmolive Company | Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions |
| NZ237570A (en) * | 1990-04-13 | 1993-09-27 | Colgate Palmolive Co | Enzyme stabilising composition and stabilised enzyme-containing built detergent compositions |
| EP0606217B2 (de) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen |
| ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| EP0654973A4 (de) * | 1992-07-21 | 1995-08-09 | Gen Hospital Corp | Anordnung zur abgabe von medikamenten an das lymphgewebe. |
| US5378601A (en) | 1992-07-24 | 1995-01-03 | Montefiore Medical Center | Method of preserving platelets with apyrase and an antioxidant |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5279565A (en) | 1993-02-03 | 1994-01-18 | Localmed, Inc. | Intravascular treatment apparatus and method |
| JP3158758B2 (ja) * | 1993-02-19 | 2001-04-23 | 松下電器産業株式会社 | 端末アダプタ装置とデータ伝送方法 |
| US6179817B1 (en) | 1995-02-22 | 2001-01-30 | Boston Scientific Corporation | Hybrid coating for medical devices |
| EP0815252A1 (de) | 1995-03-24 | 1998-01-07 | Novartis AG | Gentherapie für transplantation und entzündliche oder thrombotische zustände |
| US5811510A (en) * | 1995-04-14 | 1998-09-22 | General Hospital Corporation | Biodegradable polyacetal polymers and methods for their formation and use |
| AU5893796A (en) * | 1995-06-07 | 1996-12-30 | Novo Nordisk A/S | Modification of polypeptides |
| US6312921B1 (en) | 1996-07-26 | 2001-11-06 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US6248327B1 (en) | 1998-09-11 | 2001-06-19 | Vanderbilt University | Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis |
| NZ511488A (en) | 1998-10-16 | 2003-10-31 | Immunex Corp | Inhibitors of platelet activation and recruitment comprising an Ala residue and heterologous peptides capable of forming a stable secondary structure attached to a CD39 polypeptide |
| US6822086B1 (en) * | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| US7160924B2 (en) | 2002-07-19 | 2007-01-09 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| DE60323936D1 (de) * | 2002-01-14 | 2008-11-20 | Gen Hospital Corp | Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung |
| ATE441706T1 (de) * | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| US20040205840A1 (en) * | 2003-04-11 | 2004-10-14 | Pioneer Hi-Bred International, Inc. | Method for reducing gene expression |
-
2003
- 2003-02-19 AT AT03716070T patent/ATE441706T1/de not_active IP Right Cessation
- 2003-02-19 DE DE60329126T patent/DE60329126D1/de not_active Expired - Lifetime
- 2003-02-19 EP EP03716070A patent/EP1585817B1/de not_active Expired - Lifetime
- 2003-02-19 EP EP09011078.4A patent/EP2138575B8/de not_active Expired - Lifetime
- 2003-02-19 WO PCT/US2003/004845 patent/WO2003070823A2/en not_active Ceased
- 2003-02-19 AU AU2003219796A patent/AU2003219796A1/en not_active Abandoned
-
2004
- 2004-08-20 US US10/922,378 patent/US7785618B2/en not_active Expired - Fee Related
-
2010
- 2010-08-27 US US12/870,030 patent/US20110044967A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2138575B1 (de) | 2013-06-19 |
| EP1585817A4 (de) | 2005-12-28 |
| US20110044967A1 (en) | 2011-02-24 |
| WO2003070823A2 (en) | 2003-08-28 |
| EP1585817A2 (de) | 2005-10-19 |
| WO2003070823A9 (en) | 2005-06-02 |
| AU2003219796A8 (en) | 2003-09-09 |
| AU2003219796A1 (en) | 2003-09-09 |
| EP1585817B1 (de) | 2009-09-02 |
| DE60329126D1 (de) | 2009-10-15 |
| US20050169968A1 (en) | 2005-08-04 |
| EP2138575B8 (de) | 2013-07-24 |
| WO2003070823A3 (en) | 2004-08-26 |
| EP2138575A1 (de) | 2009-12-30 |
| US7785618B2 (en) | 2010-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60329126D1 (de) | Konjugate mit biologisch abbaubarem polymer und verwendung dafür | |
| EP1196444B8 (de) | Exendin-4 konjugate und ihre medizinische verwendung | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE263579T1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
| EP1409544A4 (de) | Humane dr4-antikörper und deren anwendungen | |
| ATE296116T1 (de) | Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie | |
| BR0014078A (pt) | Inibidores de fator xa | |
| BR0100084A (pt) | Lagarta de borracha sem-fim e veìculo contendo tal lagarta | |
| CY1109151T1 (el) | Αντισωματα dr4 και χρησεις αυτων | |
| BR0308090A (pt) | conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos | |
| MXPA03010085A (es) | Composiciones y su uso en la hiperplasia. | |
| ATE336255T1 (de) | Hyaluronsäure-ester zur behandlung von normotrophischen hautnarben | |
| ATE444086T1 (de) | Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln | |
| DE60143065D1 (de) | Bildgebende Verfahren, Diagnose und Behandlung von Krankheiten | |
| BR0007666A (pt) | Composição cosmética com base em mentol e mentil lactato, tendo pouco odor e sendo não irritante | |
| DE60140864D1 (de) | Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican | |
| PT1150716E (pt) | Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao | |
| WO2000050023A3 (en) | Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases | |
| BR9815275A (pt) | Artigo absorvente e processo para dobrar e manter um painel lateral dobrado durante um processo de produção contìnuo de artigos absorventes descartáveis | |
| UA49496A (uk) | Спосіб лікування уражень суглобів при ревматичних захворюваннях | |
| DE59706692D1 (de) | Konjugat, geeignet zur bindung von substanzen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |